In the RESPECT randomized trial (trastuzumab ± chemotherapy) in women aged 70–80 with HER2-positive early breast cancer, tumor/immune profiling with HER2DX stratified prognosis and helped identify when chemotherapy may be avoided. This evidence concerns the gene ERBB2 and neoplasm.